Clinical Trials for Esophageal Cancer

201803092

A Phase II Study of Proton Beam Therapy in the Treatment of Esophageal Cancer Phase II Principal Investigator Badiyan, Shahed Disease Site Esophagus Learn more about this study at: clinicaltrials.gov

201808178

A Phase II study of chemotherapy and immune checkpoint blockade with Pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma. Phase II (Cancer Control) Principal Investigator Park, Haeseong Disease Site…

201908202

A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer Phase II/III Principal Investigator…

201909019

Phase I Study of Radiation Dose Intensification with Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer Phase I Principal Investigator Badiyan, Shahed Disease Site Esophagus Learn more about…

201909063

A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Phase I Principal Investigator Pedersen, Katrina Disease Site Colon; Other Digestive Organ; Rectum; Stomach Learn more…

201912097

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors Phase I Principal Investigator Adkins, Douglas Disease Site Kidney; Larynx; Lip, Oral…

202001128

A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors Phase Early Phase I (Cancer Control) Principal Investigator Park,…

202006133

A phase 1b/2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy for HER2+ gastrointestinal cancers Phase I/II Principal Investigator Park, Haeseong Disease Site Colon; Esophagus; Other Digestive Organ; Rectum;…

202007167

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA Phase III Principal Investigator Park, Haeseong Disease Site Esophagus…

202012018

Phase II study of short course FOLFOX chemotherapy with either Nivolumab or Nivolumab + Radiation in the first line treatment of metastatic or unresectable gastroesophageal cancers (BMS Protocol CA209-76L) Phase II Principal Investigator Park, Haeseong…

202101058

Phase III Randomized Trial of Proton Beam Therapy(PBT) versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Phase III Principal Investigator Badiyan, Shahed Disease Site Esophagus Learn more about this study at:…

202102071

A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Phase II/III Principal Investigator Park, Haeseong Disease Site Esophagus; Other Digestive Organ Learn more about this study…

202105140

Phase 1/1B study of DS-8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial) Phase I Principal Investigator Grierson, Patrick Disease Site Esophagus; Stomach Learn more about this study…